Learn about eye changes that could indicate serious health conditions, from blurry vision to persistent floaters and flashes ...

A study involving 24 participants with both migraine and dry eye disease (DED) has found that managing DED symptoms reduced migraine severity. Participants received either Systane Hydration UD (Alcon, ...

Scientists from the University of New South Wales suggest that the severity of both conditions may be reduced through the use ...

CT-132 statistically significantly reduced monthly migraine days compared with sham digital treatment after 12 weeks. The Food and Drug Administration (FDA) has granted marketing authorization to ...

MAY IS OCULAR MELANOMA AWARENESS MONTH, AND A LOCAL ORGANIZATION IS STEPPING UP TO FIGHT THIS RARE CANCER THAT AFFECTS ABOUT 25,000, 2500 PEOPLE EACH. AND EVERY YEAR. A RUN WALK IS TAKING PLACE IN ...

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency. The drug – a new dry powder ...

But if there is a frequent headache, then we should not take it lightly because these can be symptoms of migraine. Migraine problems can cause trouble in people's daily work. Migraine pain ...

Migraine sufferers usually try everything to prevent headaches from coming on, whether it's prescription medications or old wives' tales. Many will have found a go-to method that works for them ...

Its use as a medical treatment is now widely accepted. When Kate Brayden’s migraines worsened two years ago, she knew that it was time to go under the needle. When we think of Botox, our ...

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...

CGRP antagonists are a new class of drugs designed to prevent migraine headaches by targeting a key molecule involved in pain transmission. Calcitonin gene-related peptide (CGRP) monoclonal ...